Zacks Investment Research cut shares of Swedish Orphan Bio (OTCMKTS:SWTUY) from a buy rating to a hold rating in a research report released on Friday.
According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “
Swedish Orphan Bio stock opened at $17.30 on Friday. Swedish Orphan Bio has a 12-month low of $12.55 and a 12-month high of $17.60. The company has a quick ratio of 1.21, a current ratio of 1.72 and a debt-to-equity ratio of 0.08.
Swedish Orphan Bio Company Profile
Swedish Orphan Biovitrum AB (publ), an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally. Its core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Xiapex for the treatment of Dupuytrens contracture and Peyronies disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Swedish Orphan Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Bio and related companies with MarketBeat.com's FREE daily email newsletter.